# A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

> **NCT02804178** · PHASE2 · COMPLETED · sponsor: **Millendo Therapeutics, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** ATR-101

## Key facts

- **NCT ID:** NCT02804178
- **Lead sponsor:** Millendo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-18
- **Primary completion:** 2017-08-17
- **Final completion:** 2017-08-17
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02804178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02804178, "A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02804178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*